Clinical Trial Update: Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 neoadjuvant trial of ensartinib for ALK-positive resectable stage II to III non-small cell lung cancer is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Ensartinib (Ensartinib)

Snippet

Sponsor: West China Hospital | Conditions: Non-Small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING